Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGCNASDAQ:DMACNYSEAMERICAN:MAIANASDAQ:NBTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGCCanopy Growth$1.19-4.0%$1.42$0.77▼$8.65$227.99M0.756.15 million shs9.74 million shsDMACDiaMedica Therapeutics$3.65+1.1%$3.96$2.14▼$6.82$154.81M1.2387,989 shs217,608 shsMAIAMAIA Biotechnology$1.73-7.5%$1.84$1.40▼$4.24$56.67M0.03221,047 shs240,250 shsNBTXNanobiotix$4.45-0.5%$3.92$2.76▼$6.00$210.68M0.3615,697 shs1,877 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGCCanopy Growth-4.03%-17.93%-34.97%+8.18%-82.63%DMACDiaMedica Therapeutics+1.11%+3.99%-10.10%-20.13%+68.98%MAIAMAIA Biotechnology-7.49%+0.58%+1.17%+10.19%-45.08%NBTXNanobiotix-0.47%-10.75%+17.11%+23.07%+6.95%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCGCCanopy Growth2.4168 of 5 stars2.52.00.00.02.60.01.3DMACDiaMedica Therapeutics1.325 of 5 stars3.51.00.00.02.50.00.0MAIAMAIA Biotechnology1.3926 of 5 stars0.05.00.00.01.73.30.0NBTXNanobiotix2.1794 of 5 stars3.35.00.00.01.10.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGCCanopy Growth 1.00Sell$2.0068.07% UpsideDMACDiaMedica Therapeutics 3.00Buy$8.00119.18% UpsideMAIAMAIA Biotechnology 0.00N/AN/AN/ANBTXNanobiotix 2.50Moderate Buy$8.0079.82% UpsideCurrent Analyst Ratings BreakdownLatest MAIA, NBTX, DMAC, and CGC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/30/2025CGCCanopy GrowthPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingUnderweight ➝ Underweight5/29/2025DMACDiaMedica TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.004/4/2025NBTXNanobiotixGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $8.00(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGCCanopy Growth$225.65M0.97N/AN/A$1.90 per share0.63DMACDiaMedica TherapeuticsN/AN/AN/AN/A$0.95 per shareN/AMAIAMAIA BiotechnologyN/AN/AN/AN/A$0.14 per shareN/ANBTXNanobiotix-$11.61M-18.06N/AN/A($1.51) per share-2.95Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGCCanopy Growth-$429.86M-$4.04N/AN/AN/A-195.76%-88.54%-40.78%8/8/2025 (Estimated)DMACDiaMedica Therapeutics-$24.44M-$0.64N/AN/AN/AN/A-61.35%-55.53%8/6/2025 (Estimated)MAIAMAIA Biotechnology-$23.25M-$1.38N/AN/AN/AN/A-474.86%-146.56%8/8/2025 (Estimated)NBTXNanobiotix-$73.73MN/A0.00N/AN/AN/AN/AN/AN/ALatest MAIA, NBTX, DMAC, and CGC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/30/2025Q4 2025CGCCanopy Growth-$0.28-$0.94-$0.66-$1.00$71.84 million$45.30 million5/13/2025Q1 2025DMACDiaMedica Therapeutics-$0.18-$0.18N/A-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGCCanopy GrowthN/AN/AN/AN/AN/ADMACDiaMedica TherapeuticsN/AN/AN/AN/AN/AMAIAMAIA BiotechnologyN/AN/AN/AN/AN/ANBTXNanobiotixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGCCanopy Growth0.623.122.10DMACDiaMedica TherapeuticsN/A8.028.02MAIAMAIA BiotechnologyN/A2.352.35NBTXNanobiotixN/A1.041.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGCCanopy Growth3.33%DMACDiaMedica Therapeutics10.12%MAIAMAIA Biotechnology5.65%NBTXNanobiotix38.81%Insider OwnershipCompanyInsider OwnershipCGCCanopy Growth1.30%DMACDiaMedica Therapeutics7.30%MAIAMAIA Biotechnology32.32%NBTXNanobiotix3.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGCCanopy Growth3,150183.87 million181.48 millionOptionableDMACDiaMedica Therapeutics2042.88 million39.75 millionOptionableMAIAMAIA Biotechnology930.31 million20.51 millionNot OptionableNBTXNanobiotix10047.13 million45.51 millionNot OptionableMAIA, NBTX, DMAC, and CGC HeadlinesRecent News About These CompaniesShort Interest in Nanobiotix S.A. (NASDAQ:NBTX) Declines By 89.1%June 11, 2025 | marketbeat.comNanobiotix (NASDAQ:NBTX) Stock Price Up 1.1% - Here's WhyJune 4, 2025 | marketbeat.comShort Interest in Nanobiotix S.A. (NASDAQ:NBTX) Grows By 1,197.9%May 30, 2025 | marketbeat.comNANOBIOTIX to Participate in the Jefferies Global Healthcare Investor ConferenceMay 28, 2025 | globenewswire.comNanobiotix Provides First Quarter 2025 Operational and Financial UpdateMay 21, 2025 | globenewswire.comNanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQMay 12, 2025 | globenewswire.comNanobiotix Reveals Favorable Results Of JNJ-1900 Study Pancreatic Cancer; Seeks Further EvaluationMay 5, 2025 | finanznachrichten.deNanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic CancerMay 5, 2025 | globenewswire.comNanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference CallApril 30, 2025 | globenewswire.comNanobiotix price target lowered to $8 from $12 at GuggenheimApril 5, 2025 | markets.businessinsider.comNanobiotix (NBTX) Gets a Hold from UBSApril 5, 2025 | markets.businessinsider.comNanobiotix S.A. (NBTX) Q4 2024 Earnings Call TranscriptApril 3, 2025 | seekingalpha.comNANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial ResultsApril 2, 2025 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Nanobiotix (NBTX) and PTC Therapeutics (PTCT)April 2, 2025 | theglobeandmail.comNANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025March 31, 2025 | globenewswire.comNanobiotix reports promising NSCLC treatment study resultsMarch 29, 2025 | investing.comNanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLCMarch 27, 2025 | globenewswire.comNANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3)March 21, 2025 | djournal.comNANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer ConferenceMarch 20, 2025 | globenewswire.comNanobiotix amends global licensing agreement with Janssen PharmaceuticaMarch 18, 2025 | markets.businessinsider.comNANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026March 17, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMAIA, NBTX, DMAC, and CGC Company DescriptionsCanopy Growth NASDAQ:CGC$1.19 -0.05 (-4.03%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$1.21 +0.02 (+1.68%) As of 06/23/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.DiaMedica Therapeutics NASDAQ:DMAC$3.65 +0.04 (+1.11%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$3.66 +0.00 (+0.14%) As of 06/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.MAIA Biotechnology NYSEAMERICAN:MAIA$1.73 -0.14 (-7.49%) Closing price 06/23/2025 04:10 PM EasternExtended Trading$1.76 +0.03 (+1.50%) As of 06/23/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.Nanobiotix NASDAQ:NBTX$4.45 -0.02 (-0.45%) As of 06/23/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
